Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00235989
Status:
COMPLETED
Last Update Posted:
2014-05-08
First Post:
2005-10-10
Brief Title:
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron to Treat Relapsing-remitting Multiple Sclerosis
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
An Open-label Extension Study of the Double-blind Randomized Parallel Group Multicenter Phase 2 Study 307000A to Further Evaluate the Safety and Tolerability of Betaseron 500 mcg Subcutaneously Every Other Day and Betaseron 250 mcg Subcutaneously Every Other Day in Patients With Relapsing-remitting Multiple Sclerosis RRMS
Status:
COMPLETED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis
Detailed Description:
This study has previously been posted by Berlex Inc Berlex Inc has been renamed to Bayer HealthCare Pharmaceuticals Inc
Bayer HealthCare Pharmaceuticals Incis the sponsor of the trial
Bayer HealthCare Pharmaceuticals Incis the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Beyond | OTHER | Company internal | None |
| 307320 | OTHER | None | None |